CL2019000511A1 - Inhibidores de procesos metabólicos celulares. - Google Patents

Inhibidores de procesos metabólicos celulares.

Info

Publication number
CL2019000511A1
CL2019000511A1 CL2019000511A CL2019000511A CL2019000511A1 CL 2019000511 A1 CL2019000511 A1 CL 2019000511A1 CL 2019000511 A CL2019000511 A CL 2019000511A CL 2019000511 A CL2019000511 A CL 2019000511A CL 2019000511 A1 CL2019000511 A1 CL 2019000511A1
Authority
CL
Chile
Prior art keywords
inhibitors
metabolic processes
cellular metabolic
compounds
cellular
Prior art date
Application number
CL2019000511A
Other languages
English (en)
Inventor
Zenon D Konteatis
Zhihua Sui
Jeremy M Travins
Zhixiong Ye
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59846695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000511(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/CN2016/097524 external-priority patent/WO2018039972A1/en
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of CL2019000511A1 publication Critical patent/CL2019000511A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN PROPORCIONA COMPUESTOS INHIBIDORES DE MAT2A QUE SON DE UTILIDAD COMO AGENTES TERAPÉUTICOS PARA TRATAR MALIGNIDADES Y EN DONDE LOS COMPUESTOS ESTÁN DE ACUERDO CON LA FÓRMULA GENERAL (IA), EN DONDE RA, RB, RC, RD Y RE SE DEFINEN EN LA PRESENTE.
CL2019000511A 2016-08-31 2019-02-26 Inhibidores de procesos metabólicos celulares. CL2019000511A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/097524 WO2018039972A1 (en) 2016-08-31 2016-08-31 Inhibitors of cellular metabolic processes
US201762548738P 2017-08-22 2017-08-22

Publications (1)

Publication Number Publication Date
CL2019000511A1 true CL2019000511A1 (es) 2019-05-17

Family

ID=59846695

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000511A CL2019000511A1 (es) 2016-08-31 2019-02-26 Inhibidores de procesos metabólicos celulares.

Country Status (19)

Country Link
US (4) US10329298B2 (es)
EP (1) EP3507290A1 (es)
JP (2) JP6832430B2 (es)
KR (1) KR102411150B1 (es)
CN (1) CN109890822B (es)
AU (2) AU2017319500C1 (es)
CA (1) CA3034705C (es)
CL (1) CL2019000511A1 (es)
CO (1) CO2019002237A2 (es)
CR (1) CR20190157A (es)
IL (1) IL265115B (es)
MA (1) MA46092A (es)
MX (1) MX390277B (es)
NI (1) NI201900019A (es)
PE (1) PE20190761A1 (es)
SG (1) SG11201901747VA (es)
TW (1) TWI762505B (es)
UA (1) UA125852C2 (es)
WO (1) WO2018045071A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
WO2019040499A2 (en) * 2017-08-21 2019-02-28 Navigen, Inc. ARF6 INHIBITORS AND ASSOCIATED METHODS
MX2020002869A (es) 2017-09-15 2020-07-24 Aduro Biotech Inc Compuestos de pirazolopirimidinona y usos de los mismos.
HUE066282T2 (hu) * 2018-03-30 2024-07-28 Servier Lab Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra
US12503467B2 (en) 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US20220098203A1 (en) * 2018-12-27 2022-03-31 Les Laboratoires Servier Sas Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
KR20250093588A (ko) * 2018-12-27 2025-06-24 르 라보레또레 쎄르비에르 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
WO2020167952A1 (en) * 2019-02-12 2020-08-20 Mirati Therapeutics, Inc. Mat2a inhibitors
US20220133727A1 (en) * 2019-02-13 2022-05-05 Les Laboratoires Servier Sas Combination therapies for use in treating cancer
WO2021023609A1 (en) 2019-08-02 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
CR20220308A (es) 2019-11-25 2022-08-04 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2021158792A1 (en) * 2020-02-04 2021-08-12 Agios Pharmaceuticals, Inc. Methods of treating autoimmune or inflammatory diseases or disorders
KR20230026479A (ko) 2020-06-22 2023-02-24 에프. 호프만-라 로슈 아게 설폰 유도체
WO2021254529A1 (zh) * 2020-07-14 2021-12-23 江苏先声药业有限公司 双环类化合物
CN113999232B (zh) * 2020-07-28 2025-01-07 南京正大天晴制药有限公司 Mat2a抑制剂
CA3176912A1 (en) * 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers
AR123227A1 (es) * 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Terapias combinadas para su uso en el tratamiento del cáncer
AR123228A1 (es) 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Formas en estado sólido de un compuesto orgánico
WO2022063128A1 (zh) * 2020-09-24 2022-03-31 上海凌达生物医药有限公司 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用
CN116782903A (zh) * 2020-10-15 2023-09-19 南京再明医药有限公司 取代的吡啶酮化合物及应用
US20220169654A1 (en) * 2020-11-25 2022-06-02 Servier Pharmaceuticals Llc New Organic Compounds
US20240124454A1 (en) 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2022189379A1 (en) 2021-03-08 2022-09-15 Technische Universität München Treatment of coronavirus infections using sam cycle inhibitors
CN117396480A (zh) * 2021-03-26 2024-01-12 奥弗恩制药公司 吡唑并嘧啶酮化合物
AU2022254674A1 (en) * 2021-04-08 2023-10-12 Genentech, Inc. Oxazepine compounds and uses thereof in the treatment of cancer
JP2024116429A (ja) * 2021-07-06 2024-08-28 国立研究開発法人産業技術総合研究所 組織の老化を予防または治療するための組成物
CN115716831B (zh) * 2021-08-25 2024-07-02 中国科学院分子细胞科学卓越创新中心 一种mat2a抑制剂及其在抗病毒中的应用
CN118265700A (zh) * 2021-11-09 2024-06-28 上海海雁医药科技有限公司 取代的萘啶酮衍生物、其药物组合物及应用
WO2023086934A1 (en) * 2021-11-12 2023-05-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a taxane
CN116283994B (zh) * 2021-12-20 2025-01-07 艾立康药业股份有限公司 作为mat2a抑制剂的杂环化合物
CN118414338A (zh) 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
CN116987084B (zh) * 2022-04-26 2026-02-06 上海交通大学 吡唑并嘧啶类化合物及其盐、溶剂合物、组合物和应用
WO2024080788A1 (ko) 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도
WO2024105553A1 (en) * 2022-11-16 2024-05-23 Novartis Ag Bicyclic heterocycles and their use as wrn inhibitors
CN117777134B (zh) * 2022-12-19 2025-02-25 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物
CN116425721B (zh) * 2022-12-19 2024-02-02 艾立康药业股份有限公司 作为mat2a抑制剂的双环类化合物
WO2024153244A1 (zh) * 2023-01-20 2024-07-25 南京再明医药有限公司 含氮类化合物
WO2024230828A1 (en) * 2023-05-11 2024-11-14 InventisBio Co., Ltd. Compounds, preparation methods and uses thereof
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
WO2025072544A1 (en) 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
DE3686228T3 (de) 1985-09-17 1997-08-28 Konishiroku Photo Ind Wärmeentwickelbares lichtempfindliches Material.
US4950585A (en) 1987-08-18 1990-08-21 Konica Corporation Coupler for photographic use
JPH01271751A (ja) 1988-04-23 1989-10-30 Konica Corp 新規な写真用カプラーを含有するハロゲン化銀カラー写真感光材料
JPH03172839A (ja) 1989-12-01 1991-07-26 Konica Corp 新規な写真用カプラー
JPH04133055A (ja) 1990-09-25 1992-05-07 Konica Corp 色再現性の改良されたハロゲン化銀カラー写真感光材料
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
JPH05125079A (ja) 1991-11-05 1993-05-21 Otsuka Pharmaceut Factory Inc ピラゾロ［１，５−ａピリミジン誘導体
JPH07253630A (ja) 1994-03-15 1995-10-03 Konica Corp 直接ポジハロゲン化銀カラー写真感光材料及び直接ポジカラー画像形成方法
DE59608203D1 (de) 1995-05-09 2001-12-20 Basf Ag PYRAZOLO- 1,5a]-PYRIMIDINE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
JPH095630A (ja) 1995-06-15 1997-01-10 Nikon Corp 光走査方法
FR2746309B1 (fr) 1996-03-22 1998-04-17 Oreal Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
FR2750048B1 (fr) 1996-06-21 1998-08-14 Oreal Compositions de teinture des fibres keratiniques contenant des derives pyrazolo-(1, 5-a)-pyrimidine, procede de teinture, nouveaux derives pyrazolo-(1, 5-a)-pyrimidine et leur procede de preparation
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US5817663A (en) 1996-10-07 1998-10-06 American Cyanamid Company Pentafluorophenylazolopyrimidines
JP2001521522A (ja) 1997-04-15 2001-11-06 ジェネンテック，インコーポレーテッド 新規なハロ−アルコキシカルボニルプロドラッグ
FR2767685B1 (fr) 1997-09-01 2004-12-17 Oreal Composition pour la teinture d'oxydation des fibres keratiniques comprenant du 2-chloro 6-methyl 3-aminophenol et une base d'oxydation, et procede de teinture
FR2779952B1 (fr) 1998-06-19 2000-08-04 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine a titre de base d'oxydation et un coupleur pyridinique, et procedes de teinture
US20020062529A1 (en) 1998-06-19 2002-05-30 L'oreal S.A. Dye composition containing 1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane, an additional oxidation base and a coupler, and dyeing processes
FR2779950B1 (fr) 1998-06-19 2004-05-21 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
FR2779948B1 (fr) 1998-06-19 2004-04-23 Oreal Composition tinctoriale contenant du 1,8-bis- (2,5-diaminophenoxy)-3,5-dioxaoctane, une base d'oxydation additionnelle et un coupleur, et procedes de teinture
FR2779951B1 (fr) 1998-06-19 2004-05-21 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine a titre de base d'oxydation et un coupleur naphtalenique, et procedes de teinture
FR2779949B1 (fr) 1998-06-19 2004-05-21 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
JP2000089418A (ja) 1998-09-08 2000-03-31 Konica Corp 画像記録材料、直接ポジ型ハロゲン化銀写真感光材料及び画像形成方法
FR2784380B1 (fr) 1998-09-25 2002-09-06 American Cyanamid Co Triazolopyrimidines 7-oxy- et 7-thio-substituees fongicides
US6277857B1 (en) 1998-09-25 2001-08-21 American Cyanamid Company Fungicidal 7-oxy-and 7-thio-substituted-triazolopyrimidines
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
FR2785183B1 (fr) 1998-11-04 2002-04-05 Oreal COMPOSITION TINCTORIALE CONTENANT UN COLORANT DIRECT CATIONIQUE ET UNE PYRAZOLO-[1,5-a]- PYRIMIDINE A TITRE DE BASE D'OXYDATION, ET PROCEDES DE TEINTURE
JP2000153671A (ja) 1998-11-20 2000-06-06 Fuji Photo Film Co Ltd 感熱記録材料
FR2791563A1 (fr) 1999-03-29 2000-10-06 Oreal Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition
FR2791562B1 (fr) 1999-03-29 2004-03-05 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
JP4193285B2 (ja) 1999-06-04 2008-12-10 コニカミノルタホールディングス株式会社 カラートナー
US6420057B1 (en) 1999-07-05 2002-07-16 Konica Corporation Organic electroluminescent element
JP2003510325A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
EP1218381B1 (en) 1999-09-30 2006-12-06 Neurogen Corporation AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES
US20020041880A1 (en) 2000-07-05 2002-04-11 Defeo-Jones Deborah Method of treating cancer
JP2002326462A (ja) 2001-04-27 2002-11-12 Fuji Photo Film Co Ltd 感熱記録材料
FR2831055B1 (fr) 2001-10-24 2004-05-28 Oreal Composition tinctoriale comprenant au moins une base heterocyclique et le 1-n-(b-hydroxyethyl) 4-hydroxy indole a titre de coupleur ; procedes de teinture
EP1443890B1 (de) 2001-11-17 2010-01-13 Henkel AG & Co. KGaA Oxidationsfärbemittel auf der basis zweikerniger entwicklerkomponenten
GB0130416D0 (en) 2001-12-20 2002-02-06 Eastman Kodak Co Photographic elements containing a de-aggregating compound dye-forming coupler and stabilizer
GB0130418D0 (en) 2001-12-20 2002-02-06 Eastman Kodak Co Photographic elements containing a deaggregating compound and dye forming coupler
JP2003301009A (ja) 2002-04-10 2003-10-21 Konica Minolta Holdings Inc 光重合開始剤、ラジカル発生方法、光重合組成物、平版印刷版作成用感光材料及び平版印刷版の作成方法
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
CA2494700C (en) 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
WO2004052315A2 (en) 2002-12-11 2004-06-24 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2003303094A1 (en) * 2002-12-30 2004-08-13 Exelixis, Inc. MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1599482A4 (en) 2003-02-28 2008-10-01 Teijin Pharma Ltd PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
DE602004018637D1 (de) 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
JP4795634B2 (ja) 2003-10-31 2011-10-19 出光興産株式会社 有機薄膜トランジスタ
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2005103052A1 (en) * 2004-04-21 2005-11-03 Pfizer Products Inc. Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof
GB0516378D0 (en) 2005-08-09 2005-09-14 Eirx Therapeutics Ltd Compound
US20090042856A1 (en) 2005-09-01 2009-02-12 Astellas Pharma Inc Pyridazinone derivatives used for the treatment of pain
WO2007071688A1 (en) 2005-12-22 2007-06-28 L'oréal Composition for dyeing keratin fibres with a tetraazapentamethine cationic direct dye, a particular oxidation base and a coupler
WO2007102531A1 (ja) 2006-03-08 2007-09-13 Takeda Pharmaceutical Company Limited 併用薬
MX2008011853A (es) 2006-03-17 2008-09-29 Wyeth Corp Derivados de pirazolo[1,5-a]pirimidina y sus metodos de uso.
EP2233472B1 (en) 2006-03-28 2014-01-15 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
WO2007118844A1 (de) 2006-04-13 2007-10-25 Basf Se Substituierte pyrazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
WO2008011557A2 (en) 2006-07-20 2008-01-24 Borchardt Allen J Heteroaryl inhibitors of rho kinase
WO2008019309A1 (en) 2006-08-04 2008-02-14 Metabasis Therapeutics, Inc. Novel inhibitors of fructose 1,6-bisphosphatase
WO2008046856A2 (de) 2006-10-18 2008-04-24 Basf Se Fungizide zusammensetzungen
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
JP2010510291A (ja) 2006-11-23 2010-04-02 ノバルティス アーゲー ＣＸＣＲ２アンタゴニストとしての５−スルファニルメチル−ピラゾロ［１，５−ａ］ピリミジン−７−オール
KR20090101278A (ko) * 2006-12-22 2009-09-24 인더스트리얼 리서치 리미티드 누클레오시다제 및 포스포릴라제 억제제의 아제티딘 유사체
JP5205794B2 (ja) 2007-04-26 2013-06-05 コニカミノルタホールディングス株式会社 光学フイルター用組成物、光学フィルター、ディスプレイ用前面フィルター及びスクアリリウム化合物
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2574253T3 (es) 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation Nuevo agente antiplaquetario
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
CN103037968B (zh) 2010-06-01 2016-08-24 埃克森美孚研究工程公司 加氢处理催化剂和它们的制备
RS54761B1 (sr) 2010-06-24 2016-10-31 Gilead Sciences Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
EP2402343A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole-fused bicyclic compounds
EP2402345A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
EP2402337A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402344A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds
MX2013001970A (es) 2010-08-20 2013-08-09 Hutchison Medipharma Ltd Compuestos de pirrolopirimidina y usos de los mismos.
EP2665726A4 (en) 2011-01-21 2014-09-03 Gen Hospital Corp COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES
CN110015962B (zh) * 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
WO2012149157A2 (en) * 2011-04-26 2012-11-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012154610A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive pi3k kinase inhibitors and uses thereof
WO2013059589A1 (en) 2011-10-20 2013-04-25 Sirtris Pharmaceuticals, Inc. Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US9963451B2 (en) 2013-01-31 2018-05-08 Mitsui Chemicals Agro, Inc. Fused ring pyrimidine compound and pest control agent containing the same
US9718816B2 (en) 2013-03-15 2017-08-01 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
US20160159808A1 (en) 2013-07-24 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9505767B2 (en) 2013-09-05 2016-11-29 Genentech, Inc. Pyrazolo[1,5-A]pyrimidin-7(4H)-onehistone demethylase inhibitors
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP3114127B1 (en) 2014-03-04 2017-11-29 Syngenta Participations AG Microbiocidal heterobicyclic derivatives
WO2015134770A1 (en) 2014-03-07 2015-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treating soft tissue via controlled drug release
FR3022455B1 (fr) 2014-06-20 2017-09-01 Oreal Procede de coloration des fibres keratiniques comprenant l'application d'une base d'oxydation (hetero)cyclique particuliere en l'absence d'oxydant et en milieu riche en corps gras
FR3022454B1 (fr) 2014-06-20 2017-10-06 Oreal Procede de coloration des fibres keratiniques comprenant l'application d'un colorant auto-oxydable et d'une base d'oxydation (hetero)cyclique particuliere en l'absence d'oxydant
US20170283440A1 (en) 2014-09-17 2017-10-05 Epizyme, Inc. Carm1 inhibitors and uses thereof
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
US9796722B1 (en) 2015-10-15 2017-10-24 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
US20200317674A1 (en) 2016-06-03 2020-10-08 An2H Discovery Limited Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same
WO2018039972A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
SG11201901747VA (en) 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
EP3449918A1 (en) 2017-09-01 2019-03-06 Technische Universität Dortmund Bmp-mimetics
MX2020002869A (es) 2017-09-15 2020-07-24 Aduro Biotech Inc Compuestos de pirazolopirimidinona y usos de los mismos.

Also Published As

Publication number Publication date
USRE49934E1 (en) 2024-04-23
PE20190761A1 (es) 2019-06-05
CR20190157A (es) 2019-08-13
AU2020277158A1 (en) 2020-12-24
US10800782B2 (en) 2020-10-13
JP2021073269A (ja) 2021-05-13
WO2018045071A1 (en) 2018-03-08
CA3034705C (en) 2021-08-03
AU2017319500A1 (en) 2019-04-11
US10329298B2 (en) 2019-06-25
CA3034705A1 (en) 2018-03-08
JP2019529529A (ja) 2019-10-17
TW201811797A (zh) 2018-04-01
US20180079753A1 (en) 2018-03-22
IL265115A (en) 2019-04-30
MX2019002303A (es) 2019-07-15
KR102411150B1 (ko) 2022-06-21
MA46092A (fr) 2021-04-21
NZ751515A (en) 2021-02-26
BR112019003914A2 (pt) 2019-05-28
CN109890822B (zh) 2022-08-30
JP6832430B2 (ja) 2021-02-24
US11325914B1 (en) 2022-05-10
KR20190046921A (ko) 2019-05-07
UA125852C2 (uk) 2022-06-22
SG11201901747VA (en) 2019-03-28
AU2017319500B2 (en) 2020-08-27
MX390277B (es) 2025-03-20
US20190233424A1 (en) 2019-08-01
EP3507290A1 (en) 2019-07-10
IL265115B (en) 2022-07-01
CN109890822A (zh) 2019-06-14
AU2017319500C1 (en) 2022-10-20
CO2019002237A2 (es) 2019-07-31
NI201900019A (es) 2019-04-29
TWI762505B (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
CL2019000511A1 (es) Inhibidores de procesos metabólicos celulares.
CR20150316A (es) Compuestos y sus métodos de empleo
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CR20150571A (es) Compuestos y composiciones terapéuticos
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
NI201600071A (es) Compuestos de inhibidor de autotaxina
CO2017000552A2 (es) Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70
MX2016015743A (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa.
MX370664B (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
ECSP14030779A (es) Inhibidores del nampt
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
BR112017022281A2 (pt) métodos para tratar câncer
MX2017011018A (es) Inhibicion de la actividad de olig2.
CL2019001397A1 (es) Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa.
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.